Journal of Vaccines & Vaccination

Design and production of anti-Ebola vaccines and therapeutics

11^th Global Summit and Expo on Vaccines, Vaccination and Therapeutics

September 12-14, 2016 Phoenix, USA

Charles J Arntzen

Arizona State University, USA

Keynote: J Vaccines Vaccin

Abstract:

The 2014 Ebola epidemic in West Africa brought to the world�??s attention the unmet need for vaccines to prevent this viral disease and therapeutics for post-infection use. A consortium of research groups, including Arizona State University, Kentucky Bioprocessing and Mapp Biotherapeutics collaborated to demonstrate the use of tobacco as a novel manufacturing system to manufacture both a subunit vaccine and a monoclonal antibody cocktail as a therapeutic (ZMapp). The latter was used as an experimental treatment in W. Africa and is currently considered the leading therapeutic candidate to treat Ebola outbreaks. This keynote presentation will describe the technology behind these new products and relate its use to other emerging disease targets.

Biography :

Charles J Arntzen was the Founding Director of the Biodesign Institute, Arizona State University, USA. He is an elected Member of the U.S. National Academy of Sciences and the National Academy of Inventors. He has received the USDA Award for Superior Service and served as chairman of the National Biotechnology Policy Board of NIH. From 2001-2009 he served on President Bush’s Council of Advisors on Science & Technology. Prior to joining ASU, he was Boyce Thompson Institute’s CEO (affiliated with Cornell University). His earlier administrative experience included Director of Research at the Dupont Company and Deputy Chancellor in the Texas A&M University System.

Email: Charles.Arntzen@asu.edu